Leptin plays an important role in mammary tumor formation (Candida N Pereral et al., 2008 1). It is secreted by adipose tissue that acts on the brain to regulate energy expenditure and food intake and has an important role in energy balance, insulin pathway and inflammation. Hence the aim of our investigation has been to study the impact of Lep-2548G/A polymorphism in breast cancer as compared to matched controls. This study mainly focuses on the polymorphism leptin gene for variants by a screening this gene in south Indian obese subjects (n = 154 obese breast cancer cases and n=145 obese controls). We utilized PCR-RFLP based assay to evaluate the association between the Gln2548Arg polymorphism of the leptin gene and breast cancer risk in a case control study. The distributions of all three genotypes GG, GA and AA in breast cancer cases were 18.8%, 44.8%, and 36.4% compared to that of the controls, 33.0%, 29.6%, and 37.4%. We found that postmenopausal breast cancer cases showed statistically significant association with GA genotype when compared with premenopausal women without the disease (p= 0.001). This difference was between the cases and controls in the Gln2548Arg genotypes. Our findings suggest that the LEP Gln2548Arg polymorphism may be a useful biomarker associated with the risk of breast cancer women in Indian population.
Introduction
Obesity is a major health problem that is positively associated with breast cancer incidence and subsequent mortality (Garofalo and Surmacz, 2006; Lorincz and Sukumar, 2006) . Obesity, a pandemic in India, leads to increased levels of fat in the body. Body fat is an important tissue for estrogen production and hence exogenous estrogen could increase the risk of breast cancer. Adipose-tissue-derived signaling molecules, including the adipokines, are emerging as key candidate molecules that link obesity with cancer. Adipokines, particularly leptin, therefore have important roles in breast cancer biology. The leptin gene is located on chromosome7q31.3 (Green ED et al., 1995) and expresses a 4.5 kb mRNA in adipose tissue (Zhang Y et al., 1994) . Leptin, a 16 kDa cytokine, acts as a regulator of body weight and energy balance, a product of the OB gene synthesized from white adipose tissue which influences food intake and energy expenditure (Campfield LA et al.,1995; 6, Halaas JL et al., 1995) . Leptin has recently been reported to stimulate the proliferation of various cell types and is considered to be a new growth factor. Hyperleptinemia is a common feature of obese women who have a risk of breast cancer higher than those with normal weight subjects. The function of leptin is mediated through the leptin receptor, and both leptin and its receptor are involved in the homeostatic control of appetite, weight, metabolism and reproductive functions in women (Friedman and Halaas., 1998) . The primary function of leptin is to regulate energy balance and food intake by acting in the brain, but the hormone also plays an important role in peripheral organs, modulating fertility, lactation, and immune response. Leptin levels in humans correlate with adiposity and are usually higher in females than in males (Wauters M et al., 2000) .
Adipokines, secreted by the adipose tissue, are strong candidates for the link between obesity and risk of breast cancer. The adipokine genes LEP, LEPR, and ADIPOQ influence the functional genetic variation leading to potential breast cancer risk. Mutations in the gene encoding leptin are reported to cause severe morbid obesity with hypogonadism. Our previous studies on single nucleotide polymorphisms related to breast cancer and other cancers (Kalyana Kumar Ch et al., 2007; Sabitha.K et al.,2009; Suman and Kaiser Jamil, 2006) showed that these polymorphic sites may play an important role in disease progression. Recently researchers found that women with a specific polymorphism in the LEP gene that encodes for leptin, had around twice the risk of developing breast cancer of those without these genetic variations. In breast cancer tissue, it was shown that leptin and leptin receptors are both expressed and that they act to favor cancer proliferation and metastasis (Caldefie-Chézet F et al.,2005; Ishikawa M et al.,2004) . The G-2548A polymorphism (rs7799039) in the LEP gene has been shown to affect leptin secretion in vitro and the strength of a complex formation with a nuclear protein (Hoffstedt J et al., 2002) . To obtain a better understanding of the association between leptin and breast cancer, we evaluated one variant of the LEP gene LEP (-2548) G/A genotype in a series of breast cancer cases and normal age matched obese controls.
Patients and Methods

Study population
Breast cancer patients were assessed by pathologists on the basis of clinical examinations as well as mammography and clinical-pathological examinations. The breast cancer study is a Hospital-based case-control study conducted in South Indian population. All incident breast cancer cases were newly diagnosed during the study period. Ethical Committee approved the study for the benefit of humans in general. The procedures followed were in accordance with the ethical standards of the responsible committee of the Institutes/Hospitals, to participate in a face-to-face interview using a structured questionnaire.
Selection Criteria
Senior pathologists confirmed all diagnoses. We interviewed and collected the data about the patient demographic factors; we collected the information on age, menopausal status, smoking, usual alcohol intake, BMI and previous cancer diagnoses. Participants were also asked about their family history of cancer, and the clinical information in these cases was obtained from medical records like tumor size, Grade, Axillary nodes, and whether they were receiving chemotherapy, hormonal therapy or radiotherapy. Patients were recruited following certain inclusion and exclusion criteria, which were determined before the beginning of the study.
Inclusion and Exclusion Criteria
Patients included in the study were women with breast cancer who were found to have positive (tumor-involved) axillary lymph nodes and BMI of > 27 Kg/m 2 at the time of surgery. Patients must have adequate blood counts, and adequate kidney and liver function. Patients were excluded from the study when pregnant or had significant pre-existing medical or psychiatric conditions, including a history of heart disease, or other associated diseases.
Sample collection
Based on the above criteria, a total of 154 obese breast cancer patients and 142 obese age-matched controls were enrolled in the study. Sampling was done from three major Hospitals in Hyderabad, Andhra Pradesh (India) between the period 2008 to 2011, Indo American Cancer Institute and Research Centre, Mahavir Hospital and Research Centre, and BIBI Cancer Hospital, Hyderabad A.P.
Collection of biopsy and blood samples
Tumor breast tissues (biopsies) were collected in normal saline from the pathology lab after diagnosis. The tissues were, immediately transferred and stored at -80 0 C till further processing was done. The tumor samples obtained were of various tumor sizes and diagnosed mainly as Invasive Ductal Carcinoma (IDC). About 3ml Blood samples were collected from healthy women (voluntarily) by venipuncture. These samples were used as controls, in various experiments.
Collection of demographic factors and clinical data
All patients were interviewed for recording their demographic factors like age, BMI, and other details as listed in table-1. Clinical records for ER/PR status were obtained from medical records of the patients. Similarly we could record some demographic parameters of control subjects. Where ever possible this data was correlated to obtain meaningful information to determine the risk factors of the disease. We also determined the significance of all the parameters for statistical evaluations.
Genotyping methodology
Genomic DNA was isolated by the salting-out method from the tissue samples of the cases and peripheral blood samples of the control group. The quantity of recovered DNA was determined spectrophotometrically. Polymerase chain reaction (PCR) -based restriction fragment length polymorphism (RFLP) was done to identify the leptin G2548A gene polymorphism, as described previously. The PCR primer sequences were 5-ATT CTG GCC ATC GCC GCT TC-3 (forward) and 5-CTC CTT GTT TCT TGG AAA GAG ACG-3 (reverse) (Bioserve Biotechnologies, Hyderabad, India). A three-step PCR was standardized using a Biorad system and carried out with an initial denaturation at 94 0 C for 5 minutes followed by cycling at 94 0 C for 45 seconds; 55 0 C annealing for 45 seconds, 72 0 C for 45 seconds extension and a final extension at 72 0 C for 7 minutes was carried out for about 35 cycles. Amplified PCR products were separated on 2% agarose gel, visualized with ethidium bromide stain. The amplified PCR products were subjected to RFLP using the Hha1 (Fermentas, Hanover, MD, USA) restriction enzyme for 37 0 C overnight for enzyme digestion, and visualized on 3% agarose gel stained with ethidium bromide. Three different combinations of fragment lengths were obtained in RFLP, the presence of Hha1 restriction sites which results in 60 and 182 bps correspond to GG homozygous wild types, 242bp representing AA homozygous mutants and a combination of three bands 242, 182 and 60bp represent heterozygous GA genotypes (Figure-1 
Statistical Analysis
Genotyping experiments are presented as allelic frequencies and Genotype distribution with those expected from Hardy-Weinberg Equilibrium (HWE) were made using chi square test, and Values of P (two -tailed) less than 0.05 were considered statistically significant. Odds ratio, were calculated using MedCalc for Windows, version 7.4.1.0 (MedCalc Software, Mariakerke, Belgium).
Results
Epidemiological studies
A total of 154obese breast cancer patients and 142 obese age and weight matched controls formed our study group. The distribution of biological characteristics and selected risk factors of the case controls are presented in Table 1 . The age range for breast cancer patients was 20-70 years. The mean age at which breast cancer was generally identified was 49.87 years. The study group (Breast cancer patients and controls) were divided into 5 groups according to age at diagnosis; these were 21-30, 31-40, 41-50, 51-60 and 61-70 years. Incidence of breast cancer cases was higher in the age groups 41-50 (32.4%) years when compared to other age groups, and the incidence was very low in the age group 61-70 years. The frequency of overweight and obese patients (25.9%, and 27.3%) and control (35.2%, 53.5%) showed a high body mass index (BMI>25 to <29.99). Age at menarche of BC patients showed that about 54.5% of them had attained menarche between 13 -14 years, while 18% attained it by 15-16years. This is similar to what was observed in the normal population. Depending on the menopausal status, breast cancer patients and controls were also categorized into premenopausal (48% and 57.8%) and postmenopausal groups (52% and 42.2%). It was observed the majority of sporadic breast cancer cases were higher in the postmenopausal group when compared to the premenopausal group.
Biological and other clinical Characteristics
The hormone receptor status of BC cases determined by IHC (immunohistochemistry) was categorized as ER-/PR-, ER+/ PR+, ER+/PR-and ER-/PR+. The percentage of ER-PR-(58.4%) and ER+PR+(31.2%) were high in BC cases when compared to other tumor subtypes like ER+/PR-( 6.5%) and ER-/PR+ (3.9%). The percentage of Her-2neu positive cases showed a high frequency (87.7%).
Therapeutic outcomes/ treatment of patients
We followed the case history of our study group (154 breast cancer cases) that were on chemotherapy. These breast cancer patients (present study group) received various combinations of chemotherapy for their treatment:
(i) FAC (5-Fluorouracil, Adriamycin and Cyclophosphamide) was given to 51.74% of breast cancer patients.
(ii) FEC (5-Fluorouracil, Epirubicin and Cyclophosphamide) was given in 28.82%.
(iii) FED (5-Fluorouracil, Epirubicin and Doxorubicin,) was givenin 7.2%
(iv) CMF (Cyclophosphamide, Methotrexate and 5-Fluorouracil) was given 3.6%
In the present study FAC Combination chemotherapy was more frequentlyused than the other combinations.
Genotype Analyses in Sporadic Breast Cancer Patients and Control Subjects
Breast cancer patients showed 18.8% GG, 44.8% GA and 36.4% AA genotypes when compared to controls that had 33.0% GG, 29.6% GA, and 37.4% AA genotypes respectively. Table 2 shows the results for the G5438A polymorphism, there was a significant difference in the distribution of GG and GA between patients and controls. Both the homozygous wild type genotype GG and heterozygous genotypes GA were more in patients when compared to controls. The G2548A had a 
Leptin 2548 G/A genotype association with breast cancer
We next analyzed the correlation of Leptin 2548 G/A genotype association with breast cancer patients and demographic factors. From the correlation analysis of three different genotypes with the age of diagnosis in BC patients GA genotype showed a high frequency in both early (age group 31-40) and late (age group 51-60) onset of the disease was highly significant (p = 0.0001). The difference in the distribution of GA genotype between pre and postmenopausal showed that GA genotype was significantly (p = 0.0001) associated with postmenopausal breast cancer women. Estrogen and progesterone receptors served as prognostic markers and predicted response to endocrine therapy. In the present study, genotypes were correlated with ER/PR status to find whether these polymorphisms showed any association with ER//PR status. It was observed that GA genotype showed a high frequency in both ER/PR positive and ER/PR negative Breast Cancer patients (p = 0.0001 and (p = 0.0002) ( Table-3) . 
Discussion
Leptin that binds to receptors in the brain and performs several functions may prove important in treating obesity. Recently, leptin has been associated with cancers of the, ovary, prostate, small lung cancer and with endometrial cancers and also plays an important role in tumorogenesis has been proposed by observations from the previous studies Chovanec J et al., 2009) . Folic acid and gene polymorphism were found to be significantly related to the overweight/ obese subjects (Thawnashom et al., 2005) . In our earlier studies MTHFR C677T 1298 was shown to be good biomarkers for breast cancer and Acute lymphoblastic leukemia (Haranatha Reddy and Kaiser Jamil,2006; Marianna Terrasi and Elena Fiorio,2009 ).
The Leptin-2548G/A polymorphism in the gene promoter region has previously been implicated in its association with the degree of obesity. New data also suggests the link between Lep-2548G/A and risk of neoplastic disease (Wauters M et al., 2000) . Leptin gene G5438A polymorphism could play a crucial role in the pathogenesis of breast cancer in obese patients. Due to this polymorphism, the change in amino acid sequence is affected, which results in a change in leptin expression, this modulation is followed by a whole metabolism alteration. But on the other hand leptin gene expression can also be induced, it is therefore suggested that this polymorphism can promote carcinogenesis. In this case-control study carried out in the south Indian population, we investigated the effects of -2548 G/A polymorphism in the gene encoding for leptin on breast cancer risk in obese breast cancer cases, and age-matched obese controls. The present study revealed significant differences in genotypes distribution of investigated polymorphism for breast cancer risk. The occurrence of Lep-2548G/A can enhance leptin expression in breast cancer cells via Sp1-and nucleolin-dependent mechanisms and possibly contribute to intra-tumoral leptin overexpression (Marianna Terrasi and Elena Fiorio., 2009) . GA genotype was also significantly associated with obesity and being overweight, thus suggesting that G2548A polymorphism is associated with obesity and breast cancer susceptibility.
Thus our results indicated that the G2548A polymorphism in LEP gene is associated with increased breast cancer, as well as disease progression, supporting our hypothesis for leptin involvement in breast cancer pathogenesis in the Indian population. The results reported by Snoussi et al. (2006) 's showed that individuals with the LEP polymorphism had a higher risk of developing breast cancer than individuals who do not have it. The risk increased for individuals with two copies of the polymorphism (homozygote) and these subjects had a threefold higher risk of developing breast cancer than individuals who do not have the polymorphism at all (Kaouther Snoussi et al., 2006) . Li-Qiang Wang et al. (2012) in a pooled analysis suggested that Gln2548Arg polymorphism significantly correlated with breast cancer risk. Recently, a Tunisian group investigated the prognostic value of polymorphisms in leptin gene 5' promoter region and found a decreased DFS in breast carcinoma patients with the 2548A allele (K. Snoussi et al., 2006) . On the other hand, it has been shown that the genotype 2548 G/A was significantly associated with obesity, compared with the homozygous G/G genotype (M. F. Mnif et al., 2009) . Taken together, the results of these two studies suggest that the risk of breast cancer recurrence increased in obese patients, which are in consistent with our findings.
Previous reports demonstrated that Leptin (-2548) A allele was significantly associated with higher leptin levels (Le Stunff C et al., 2000) . The LEP (-2548) A allele, which result in high leptin secretion, was associated with increased risk of prostate cancer . In our study GA genotype was significantly elevated in postmenopausal breast cancer women. LEP (-2548) A allele was significantly associated with higher leptin levels. Mantzoros et al. (1999) observed that leptin did not appear to increase the risk of pre-menopausal breast cancer in situ (Kaouther Snoussi et al. 2006) suggest that leptin increased the risk of breast cancer independently of menopausal status. The finding of interaction between LEPRGln2548Arg genotypes, menopausal status and obesity may also partly explain the differences in reports from various populations. In developed countries with a much higher percentage of postmenopausal breast cancer and a higher proportion of obese women, LEPR Gln2548Arg polymorphism may be expected to have more impact on the risk of the disease further this polymorphism existing in the Indian population and can form a good biomarker.
Conclusion
In conclusion, the genetic variants of LEP-2548 G/ A is a relevant biomarker of breast cancer risk in Indian population. This study also has demonstrated a modestly increased risk of postmenopausal breast cancer in women harboring Gln2548Arg polymorphism of the leptin gene.
To the best of our knowledge, ours is the first study to provide information on the role of LEPR Gln2548Arg polymorphism in obese breast cancer risk in South Indian women.
